Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of LUNA18 alone and with cetuximab in advanced solid tumors
jRCT2031210282Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cyclic Peptides → Modified Peptides → Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of paluratide and cetuximab in Nonhematologic neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety, Efficacy and 3 more. Started Oct 2021; status: completed.
02
Drugs
paluratidecetuximab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210282.